Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00836199 · ClinicalTrials.gov registry record · Phase 3
NicVAX/Placebo as an Aid for Smoking Cessation
A Phase 3 study, sponsored by Nabi Biopharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,000
- Enrollment target
NCT00836199 is a Phase 3 study that has completed, run by Nabi Biopharmaceuticals. The registered enrollment target is 1,000 participants.
The verdict
NCT00836199, a Phase 3 study, has completed, sponsored by Nabi Biopharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,000 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate NicVAX as an aid to smoking cessation for long term abstinence.
Interventions
- BIOLOGICAL NicVAX vaccine
- BIOLOGICAL Placebo vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2009-10 |
| Est. Completion | 2011-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00836199
The ClinicalTrials.gov registry entry for NCT00836199 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,000 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Nabi Biopharmaceuticals, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which NicVAX vaccine is the first listed.
NCT00836199 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00836199 about?
NCT00836199 is a clinical study titled "NicVAX/Placebo as an Aid for Smoking Cessation". The purpose of this study is to evaluate NicVAX as an aid to smoking cessation for long term abstinence.
What is the current status of trial NCT00836199?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,000 participants. The study started on 2009-10. Estimated completion is 2011-07.
What interventions are being tested in trial NCT00836199?
The interventions under investigation include: NicVAX vaccine (BIOLOGICAL), Placebo vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00836199?
This trial is sponsored by Nabi Biopharmaceuticals, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.